Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR T-cell (Beijing GoBroad Hospital)
- Development stage
- Unknown
- Lead developer
- GoBroad Healthcare Group
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR T-cell (Beijing GoBroad Hospital) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen. Developed and studied by Beijing GoBroad Hospital, this specific product utilizes murine-derived single-chain variable fragments (scFv) in its CAR construct. It is primarily being evaluated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in children, adolescents, and young adults. The therapeutic approach involves the ex vivo genetic modification of a patient's own T cells to express a CAR that identifies and eliminates CD19-expressing malignant B cells. In clinical research, it is being compared as a standalone bridging therapy to hematopoietic stem cell transplantation (HSCT) or as part of a sequential infusion protocol with CD22-targeted CAR T-cells to mitigate antigen escape and improve long-term outcomes.
- Other names
- Murine-derived CD19 CAR T cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR T-cell (Beijing GoBroad Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR T-cell (Beijing GoBroad Hospital).